miR-3937在多发性骨髓瘤中的表达水平及临床诊断中的潜在应用价值

The Expression Level of miR-3937 in Plasma of Patients with Multiple Myeloma and Its Potential Application in Clinical Diagnosis

目的分析多发性骨髓瘤(MM)患者血浆中hsa-miR-3937的表达水平及其潜在的临床应用价值。方法利用GEO数据库中公开数据集筛选MM患者血浆中的差异表达基因,并通过实时荧光定量PCR方法对MM患者血浆与健康对照组预测差异miRNAs表达量进行验证。然后利用受试者工作特征曲线(ROC)分析了hsa-miR-3937诊断MM的敏感性和特异性,并通过Spearman法分析了MM患者血浆miR-3937与临床检验指标的相关性,评估其潜在的临床应用价值。结果MM患者血浆中hsa-miR-3937表达量明显高于健康对照组(P<0.01)。hsa-miR-3937的ROC曲线下面积显示hsa-miR-3937基因在诊断MM上具有较高的灵敏度和特异度。同时,通过数据还发现hsa-miR-3937表达量与血清M蛋白、骨髓中浆细胞比例呈正相关。结论实验数据结果表明hsa-miR-3937在MM患者血浆中特异性高表达,作为临床上新的诊断性标志物具有较高的灵敏度和特异度,有望成为临床潜在的新型诊断性分子标志物。

Objective To investigate the differential expression of microRNAs(miRNAs)in multiple myeloma(MM)and analyze the expression of hsa-miR-3937 in patients peripheral blood and its potential clinical utility.Methods In this study,differential miRNAs expression in MM patients'plasma was screened using an open dataset from the GEO database and validated by real-time fluorescence quantitative PCR for differences in miRNAs expression between MM patients'plasma and healthy controls.Sensitivity and specificity of hsa-miR-3937 in MM diagnosis were analyzed using the subjects'working characteristic curve(ROC)and the association of hsa-miR-3937 in MM patient plasma with various clinical indicators was analyzed by Spearman method to evaluate its potential clinical utility.Results Expression of hsa-miR-3937 significantly upregulated in MM patients compared to healthy controls(P<0.01).The area under the ROC curve of hsa-miR-3937 showed high sensitivity and specificity in the diagnosis of MM.We also found that the expression of hsa-miR-3937 was highly correlated with the expression of serum M protein and bone marrow plasma cell,which is expected to be a potential novel biomarker for the diagnosis of MM patients.Conclusion The experimental data show that hsa-miR-3937 is highly specific in the plasma of MM patients,which has high sensitivity and specificity as a new clinical diagnostic marker,and is expected to become a potential new clinical diagnostic molecular marker.